Responses
Oral Abstracts
Plenary 5: Oral Abstract Presentations
O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results
Compose a Response to This Article
Other responses
No responses have been published for this article.